| Monica Renee Hartung, PA | |
|
1655 N Gladstone Ave, Columbus, IN 47201-5392 | |
| (812) 376-3071 | |
| Not Available |
| Full Name | Monica Renee Hartung |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Location | 1655 N Gladstone Ave, Columbus, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790143865 | NPI | - | NPPES |
| 10001799A | Other | IN | LICENSE - IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 10001799A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Monica Renee Hartung, PA 1655 N Gladstone Ave, Columbus, IN 47201-5392 Ph: (812) 376-3071 | Monica Renee Hartung, PA 1655 N Gladstone Ave, Columbus, IN 47201-5392 Ph: (812) 376-3071 |
News Archive
Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech's patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.
Supratentorial cerebral infarction can cause functional inhibition of remote regions such as the cerebellum, which may be relevant to diaschisis. This phenomenon is often analyzed using positron emission tomography and single photon emission CT. However, these methods are expensive and radioactive.
Cmed Group, an innovative clinical trials services and advanced software provider, announced today that it has been selected as one of six preferred providers offering its clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The PDPs are working to develop and deliver affordable treatments and vaccines that will help improve the lives of the some of the world's most vulnerable people, especially those in developing countries.
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
› Verified 4 days ago
Dr. Christopher E Stevens, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2345 Northpark Dr, Columbus, IN 47203 Phone: 812-669-1490 Fax: 812-669-1491 | |
Anthony D Sanders, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1655 N Gladstone Ave, Ste E, Columbus, IN 47201 Phone: 812-376-3071 Fax: 812-378-5721 | |
Mrs. Ashley Elizabeth Smith, NP Otolaryngology Medicare: Medicare Enrolled Practice Location: 1655 N Gladstone Ave Ste E, Columbus, IN 47201 Phone: 812-376-3071 Fax: 812-378-5721 | |
William Earl Cooper, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 3632 Mockingbird Drive, Columbus, IN 47203 Phone: 812-372-9305 | |
Kenneth Kennedy, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1655 N Gladstone Ave Ste E, Columbus, IN 47201 Phone: 812-657-8080 Fax: 502-561-7280 | |
Frederick Porter, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1655 N Gladstone Ave, Ste E, Columbus, IN 47201 Phone: 812-376-3071 Fax: 812-378-5721 |